Solis Minerals Ltd (TSX-V:SLMN, ASX:SLM, OTCQB:SLMFF, FRA:08WA) has kicked off diamond drilling at its 100%-owned Cinto Copper Project in southern Peru, beginning an initial program of around five holes for 2,500 metres designed to test high-priority porphyry copper targets.
The program will investigate coincident geochemical and geophysical anomalies, including targets generated by induced polarisation (IP) surveying and areas where previous surface sampling returned copper grades of up to 8.7%.
First Phosphate Corp. (CSE:PHOS, NASDAQ:PHOS, FRA:KD0, OTCQX:FRSPF) said shareholders re-elected all five board nominees and approved an advance notice policy at its Annual General and Special Meeting, as the company's registered shareholder base grew 861% over the past year.
The company reported voter turnout of more than 34% at the meeting, held August 28, 2026, with all board nominees receiving support above 95%.
Blockmate Ventures Inc (TSX-V:MATE, OTCQB:MATEF, FRA:8MH) has submitted a zoning application for its Wyoming AI data centre development and announced the launch of a Bitcoin cloud mining product from investee company Hivello.
The zoning application seeks approvals for approximately 40 acres of land for data centre use, following engineering, surveying, infrastructure and local engagement work carried out in recent months.
374Water Inc (NASDAQ:SCWO, FRA:8LL) announced that it will exhibit its AirSCWO supercritical water oxidation technology at WEFTEC 2026, the Water Environment Federation’s annual technical exhibition and conference, taking place September 28 to 30 in New Orleans.
The company will showcase its Waste Destruction Services platform, which uses supercritical water oxidation to destroy PFAS, biosolids and other organic waste streams.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it has appointed Chitrang Davé as chief data and digital officer, effective August 30, creating a new executive role focused on data, analytics, artificial intelligence and digital strategy.
Davé will report to CEO Erik Lundgren and join Immunic’s executive leadership team. He will oversee an enterprise-wide organization covering data science, engineering, management and digital capabilities as the biotechnology company prepares to transition from late-stage clinical development toward potential commercialization.
TNR Gold Corp (TSX-V:TNR, FRA:TNW, OTC:TRRXF) is asking shareholders to vote for its slate of board nominees ahead of a September 22 annual meeting, as it faces a campaign from dissident shareholder Jon Christian Evensen to replace the entire board.
The company said it has filed and mailed a management information circular to shareholders, urging them to use its blue proxy form to vote for nominees John Davies, Kirill Klip, Konstantin Klip and Leopold Sutton.
Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) shares climbed on Tuesday after it announced initial certified laboratory results from its Phase 4 drilling programme at Mushima North in Zambia have confirmed broad, near-surface silver-copper-zinc mineralisation, supporting the existing exploration target as the company works towards a maiden resource estimate this year.
Among the first five holes analysed, Tertiary reported 66 metres grading 37 grams per tonne silver, 0.28% copper and 0.27% zinc from seven metres downhole, equivalent to 58 g/t silver. A further 73-metre intersection returned 45 g/t silver equivalent from nine metres, while 57 metres from 34 metres downhole graded 55 g/t silver equivalent.
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) shares climbed on Tuesday after it told investors that its Namibia joint venture has applied to move PEL 93 into its next two-year exploration phase, putting at least one exploration well on the work programme as nearby drilling provides further evidence of hydrocarbons in the Owambo Basin.
The application covers a Second Renewal Exploration Period starting on 3 October 2026 and follows integration of around 6,000 line-kilometres of airborne geophysical data.
Chariot Ltd (AIM:CHAR, OTC:OIGLF) won a vote of confidence from Cavendish on Tuesday, as the broker hiked its target price to 8.3p while leaving earnings forecasts unchanged.
The shares stood at 1.9p, up 12%, as Cavendish reiterated its 'buy' rating and tweaked its valuation model after the energy group doubled its economic footprint in Angola.
Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the life sciences company, traded at 13.4p, up 14%, in early London trade following the release of successful phase 3 clinical trial results.
Positive topline data from the LANTERN study demonstrated the efficacy of the company's nasal photodisinfection technology in preventing surgical site infections.
Connecting Excellence Group Plc (AQSE:XCE, OTCQB:XCELF) has signed binding terms for its first recruitment company acquisition, alongside a trading update showing strong growth at its flagship operating business.
The AQSE-listed executive recruitment group, which runs a Bitcoin treasury strategy alongside its recruitment operations, has agreed to buy two UK-registered companies that trade as a single specialist construction and engineering recruitment business.
Chariot Ltd (AIM:CHAR, OTC:OIGLF) told investors that a new partnership with Etu Energias and BW Energy will effectively double its economic footprint in Angola, giving it exposure to future cash flows equivalent to around 4,000 barrels of oil per day.
The AIM-listed energy group signed a framework agreement supporting Etu Energias’ acquisition of an additional 31% working interest in offshore Block 14 and 15.5% in Block 14K. In return for operational and technical support, Chariot said its interest carries an indicative net NPV10 of more than US$100 million at a US$60 per barrel oil price.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review.
The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market Performance Group as its new US commercial partner from 1 September, replacing Haleon after a two-month transition.
Greenvale Energy Ltd (ASX:GRV, OTC:GVLMF) has defined a large-scale potential uranium paleochannel target extending for around nine kilometres at the Powers Prospect within its Thunderball Uranium Project in the Northern Territory.
Field mapping and sampling have outlined a north-south trending target up to 400 metres wide, confirming an extensive airborne radiometric anomaly previously identified through Greenvale’s regional exploration work.
Frontier Energy Ltd (ASX:FHE, OTC:FRHYF) has executed all major equipment and construction contracts for Stage One of its Waroona Renewable Energy Project in Western Australia, materially reducing execution risk as the company prepares to begin site works this month.
Stage One comprises a 132-megawatt solar facility paired with an 81.5-megawatt, 6.9-hour battery energy storage system (BESS). Major equipment and construction contracts have been secured on a fixed-price basis and represent the majority of the project’s $310 million budget, with a further $22 million contingency. The development is fully funded.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has moved its compressed hydrogen technology closer to commercial-scale production after signing a technical collaboration agreement with China’s Himile Heavy Industries to develop a manufacturing pathway for its proprietary hydrogen tanks.
The agreement builds on Provaris’ prototype fabrication and class approval work in Norway and will assess large-scale production of tanks for the company’s H2Neo™ hydrogen carriers and H2Leo™ storage barges, as well as other potential applications.
Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has secured approximately $4.77 million in additional funding after Forrest Capital Pty Ltd agreed to fully underwrite the exercise of the company’s remaining unlisted options.
The agreement comes as Actinogen approaches a potentially significant clinical milestone, with topline results from its pivotal XanaMIA Phase 2b/3 Alzheimer’s disease trial expected in November 2026.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured firm commitments for a $2.3 million institutional placement, providing full funding for its newly announced clinical trial of lead oncology candidate HMBD-002 in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS).
HMBD-002 is being developed as a potential treatment for cancer, with Percheron now focused on moving the program into its next clinical phase while maintaining funding for its broader development activities.